NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/18/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization323.16 mln
Float36.47 mln
Earnings Date08/12/2026
EPS
0.95
Decent
P / E
6.07
Undervalued
Piotroski F-Score
6
/ 9
Solid
Relative Strength
41
/ 100
Slightly lagging
Debt / Equity
0.16
Very low leverage
ROE
48.60
Very strong
Business Description
Abeona Therapeutics is a US-based biopharmaceutical company focused on developing gene and cell therapies for serious, life-threatening conditions. Its leading product, ZEVASKYN, is designed to treat recessive dystrophic epidermolysis bullosa, a severe skin disorder, while its pipeline includes additional therapies targeting rare eye diseases such as X-linked retinoschisis, Stargardt disease, and autosomal dominant optic atrophy. Founded in 1974 and headquartered in Cleveland, Ohio, the company also advances a broader gene therapy platform aimed at addressing other difficult-to-treat conditions.
